Month: August 2022

Marketplace growth accelerates: Revenue increases 89% year-over-year driven by accelerating marketplace growth as well as supplier services including Thomas. Strong gross margin and gross profit trends driven by AI pricing/supplier selection and additional supplier services: Gross profit up 217% year-over-year. Marketplace gross profit increased 25% quarter-over-quarter. Expect strong growth for balance of 2022: We expect revenue growth of 81-83% to $395-$400 million, driven by increasing active buyers and suppliers, added supplier services and revenue synergies with Thomas. Expect further operating leverage: Q2 Adjusted EBITDA loss of $8.3 million, a $4.4 million quarter-over-quarter improvement. We expect operating leverage to further improve in the second half of 2022. We expect to be Adjusted EBITDA positive for 2023. Robust marketplace...

Second quarter revenues of $58.1 million, net of non-cash warrants impact of $4.5 million, in line with preliminary results issued on July 5, 2022 Second quarter GAAP operating loss of $24.9 million; Non-GAAP operating loss of $18.3 million, net of $4.5 million attributed to the non-cash impact of warrants Board of Directors approves $75 million share repurchase program Announces CFO transition; Industry veteran Lauri Hanover to join Kornit executive management team as Chief Financial OfficerROSH-HA`AYIN, Israel, Aug. 10, 2022 (GLOBE NEWSWIRE) — Kornit Digital Ltd. (“Kornit” or “the Company”) (Nasdaq: KRNT), a worldwide market leader in sustainable, on-demand, digital fashionX and textile production technologies, reported today results for the second quarter ended June 30, 2022. “While the overall operating environment remains...

– Registrational studies of SerpinPC for treatment of Hemophilia B planned for 2H of 2022 – – Oncology pipeline advancing with novel LockBody® technology – – Announces discontinuation of ZF874 for AATD – – Multiple clinical PoC readouts expected across pipeline over next two years – – Cash and cash equivalents of $484.2 million as of June 30, 2022; Cash runway into 2026 – BOSTON and LONDON, Aug. 10, 2022 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop, and ultimately deliver impactful medicines to patients, today reported financial results and business highlights for the second quarter ended June 30, 2022, and provided a program update for ZF874 for...

NEW YORK, Aug. 10, 2022 (GLOBE NEWSWIRE) — 1stdibs.com, Inc. (NASDAQ: DIBS), a leading online marketplace for luxury design products (“1stDibs” or the “Company”), today reported financial results for its second quarter ended June 30, 2022. Second Quarter 2022 Financial HighlightsNet revenue was $24.6 million, a decrease of 0.5% year-over-year. Gross profit was $16.6 million, a decrease of 4% year-over-year. Gross margin was 67.6%, compared to 70.4% in the second quarter 2021. GAAP net loss was $0.3 million and included a $9.7 million gain on the Sale of Design Manager, compared to a net loss of $4.1 million in the second quarter 2021. Non-GAAP Adjusted EBITDA and Adjusted EBITDA Margin was $(6.1) million and (24.7)%, respectively, compared to $(3.0) million and (12.3)%, respectively, in the second quarter...

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 Announced positive topline results from Phase 2 trial of Zygel in patients with 22q11.2 deletion syndrome (22q) Company focusing resources on orphan neuropsychiatric disorders, FXS and 22q $62.5 million in cash and cash equivalents at June 30, 2022; Cash runway through the end of 2023 / early 2024 DEVON, Pa., Aug. 10, 2022 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reported financial results for the second quarter ended June 30, 2022, and provided an overview of recent operational highlights and a pipeline update. “During...

Phase 1 umbrella trial for hematologic malignancies open for enrollment Publication in Cell further validates use of foundational technology to identify novel tumor antigens and effective TCRs TSC-200-A2 (HPV) and TSC-204-C7 (MAGE-A1) IND filings anticipated by year-end 2022 Appointment of Debora Barton, M.D., as Chief Medical Officer Ended quarter with cash and cash equivalents of $125.6 million, funding operations into 2024 WALTHAM, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results for the second quarter ended June 30, 2022 and provided business updates. “During the second quarter we have made...

– Patients with MTAP-deleted solid tumors being actively enrolled in ongoing Phase 1/2 trial of TNG908, an MTA-cooperative PRMT5 inhibitor – – Received Orphan Drug Designation in US for the treatment of malignant peripheral nerve sheath tumors with TNG908 – CAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the second quarter ended June 30, 2022 and provided business highlights. “We are continuing to advance our lead MTA-cooperative PRMT5 inhibitor program, TNG908, as we actively enroll patients with MTAP-deleted solid tumors in an ongoing Phase 1/2 trial,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics....

Second Quarter Net Sales Increased +13% to $115 million; For The First Six Months, Net Sales grew +19% Gross Margin of 25% Represents a Sequential Improvement of Over 500 Basis Points from the First Quarter Company Reaffirms Previously Communicated Net Sales and Adjusted EBITDA Guidance NEW YORK, Aug. 10, 2022 (GLOBE NEWSWIRE) — The Vita Coco Company, Inc. (NASDAQ: COCO) (“Vita Coco” or the “Company”), a leading high-growth platform of better-for-you beverage brands, today announced financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Highlights Compared to Prior-Year PeriodNet sales grew 13% to $115 million driven by strong 21% growth of Vita Coco Coconut Water which continues to be the largest contributor to growth on a consolidated basis.Gross profit was $29 million, flat on a dollar basis,...

Completed agreement for strategic collaboration to jointly develop and commercialize CLN-081 with Taiho Pharmaceutical Presented updated Phase 1/2a data for CLN-081 at the 100mg BID dose showing median duration of response greater than 21 months and median progression-free survival of 12 months at the American Society for Clinical Oncology (ASCO) Annual Meeting Cash and investments of $656 million1 as of June 30, 2022 expected to provide runway through 2026. CAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapeutic candidates across multiple modalities for patients with cancer, today reported on recent and upcoming business highlights and announced its financial results for the second quarter ended June...

Sales increased to $907 million, despite the normalization of residential lumber sales 10% organic growth for infrastructure-related businesses EBITDA(1) of $154 million, or a healthy margin of 17.0% Net income of $94 million, or $1.51 per share Strong cash flow generation of $228 millionMONTREAL, Aug. 10, 2022 (GLOBE NEWSWIRE) — Stella-Jones Inc. (TSX: SJ) (“Stella-Jones” or the “Company”) today announced financial results for its second quarter ended June 30, 2022. “Stella-Jones recorded solid results in the second quarter, above market performance, delivering sequentially higher margins and generating significant cash,” said Éric Vachon, President and CEO of Stella-Jones. “We are particularly pleased with the performance of our infrastructure-related businesses, which speaks highly to the wide reach of our expanded network...